Trade bluebird bio, Inc. - BLUE CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.03 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
bluebird bio Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.41 |
Open* | 1.39 |
1-Year Change* | -68.97% |
Day's Range* | 1.36 - 1.51 |
52 wk Range | 1.26-6.82 |
Average Volume (10 days) | 9.83M |
Average Volume (3 months) | 229.39M |
Market Cap | 264.59M |
P/E Ratio | -100.00K |
Shares Outstanding | 190.36M |
Revenue | 21.73M |
EPS | -0.74 |
Dividend (Yield %) | N/A |
Beta | 0.70 |
Next Earnings Date | Mar 27, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 15, 2024 | 1.41 | 0.09 | 6.82% | 1.32 | 1.44 | 1.29 |
Mar 14, 2024 | 1.32 | -0.04 | -2.94% | 1.36 | 1.37 | 1.29 |
Mar 13, 2024 | 1.38 | 0.06 | 4.55% | 1.32 | 1.44 | 1.31 |
Mar 12, 2024 | 1.33 | -0.10 | -6.99% | 1.43 | 1.43 | 1.31 |
Mar 11, 2024 | 1.39 | -0.18 | -11.46% | 1.57 | 1.64 | 1.36 |
Mar 8, 2024 | 1.48 | 0.02 | 1.37% | 1.46 | 1.63 | 1.44 |
Mar 7, 2024 | 1.43 | -0.02 | -1.38% | 1.45 | 1.49 | 1.39 |
Mar 6, 2024 | 1.44 | 0.00 | 0.00% | 1.44 | 1.52 | 1.34 |
Mar 5, 2024 | 1.37 | -0.04 | -2.84% | 1.41 | 1.49 | 1.37 |
Mar 4, 2024 | 1.52 | -0.04 | -2.56% | 1.56 | 1.58 | 1.43 |
Mar 1, 2024 | 1.54 | 0.15 | 10.79% | 1.39 | 1.65 | 1.39 |
Feb 29, 2024 | 1.37 | -0.30 | -17.96% | 1.67 | 1.72 | 1.34 |
Feb 28, 2024 | 1.67 | -0.10 | -5.65% | 1.77 | 1.85 | 1.62 |
Feb 27, 2024 | 1.73 | 0.21 | 13.82% | 1.52 | 1.90 | 1.46 |
Feb 26, 2024 | 1.44 | 0.17 | 13.39% | 1.27 | 1.50 | 1.26 |
Feb 23, 2024 | 1.23 | 0.03 | 2.50% | 1.20 | 1.30 | 1.16 |
Feb 22, 2024 | 1.17 | 0.13 | 12.50% | 1.04 | 1.18 | 1.04 |
Feb 21, 2024 | 1.08 | 0.00 | 0.00% | 1.08 | 1.12 | 1.04 |
Feb 20, 2024 | 1.09 | 0.08 | 7.92% | 1.01 | 1.11 | 1.01 |
Feb 16, 2024 | 1.01 | -0.05 | -4.72% | 1.06 | 1.06 | 0.99 |
bluebird bio, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, March 27, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2023 bluebird bio Inc Earnings Release Q4 2023 bluebird bio Inc Earnings ReleaseForecast -Previous - |
Tuesday, May 7, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 bluebird bio Inc Earnings Release Q1 2024 bluebird bio Inc Earnings ReleaseForecast -Previous - |
Friday, June 14, 2024 | ||
Time (UTC) 12:30 | Country US
| Event bluebird bio Inc Annual Shareholders Meeting bluebird bio Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 3.597 | 3.662 | 0 | 0 | 54.579 |
Revenue | 3.597 | 3.662 | 0 | 0 | 54.579 |
Total Operating Expense | 290.689 | 594.573 | 559.259 | 562.963 | 626.602 |
Selling/General/Admin. Expenses, Total | 136.908 | 209.969 | 239.95 | 235.844 | 174.129 |
Research & Development | 240.764 | 319.946 | 319.309 | 327.119 | 448.589 |
Other Operating Expenses, Total | 2.999 | ||||
Operating Income | -287.092 | -590.911 | -559.259 | -562.963 | -572.023 |
Other, Net | 22.699 | -1.748 | 0.319 | -0.684 | 1.961 |
Net Income Before Taxes | -266.461 | -562.38 | -560.37 | -555.567 | -555.438 |
Net Income After Taxes | -266.578 | -562.638 | -561.056 | -555.022 | -555.625 |
Net Income Before Extra. Items | -266.578 | -562.638 | -561.056 | -555.022 | -555.625 |
Net Income | -266.578 | -819.378 | -618.695 | -789.608 | -555.625 |
Income Available to Common Excl. Extra. Items | -266.578 | -562.638 | -561.056 | -555.022 | -555.625 |
Income Available to Common Incl. Extra. Items | -266.578 | -819.378 | -618.695 | -789.608 | -555.625 |
Diluted Net Income | -266.578 | -819.378 | -618.695 | -789.608 | -555.625 |
Diluted Weighted Average Shares | 78.585 | 68.91 | 62.178 | 55.191 | 52.032 |
Diluted EPS Excluding Extraordinary Items | -3.39222 | -8.16482 | -9.02338 | -10.0564 | -10.6785 |
Diluted Normalized EPS | -4.19504 | -7.92145 | -9.02338 | -10.0564 | -10.6785 |
Cost of Revenue, Total | 10.077 | 38.857 | 0 | 0 | 0.885 |
Gross Profit | -6.48 | -35.195 | 0 | 0 | 53.694 |
Interest Income (Expense), Net Non-Operating | -2.068 | 30.279 | -1.43 | 8.08 | 14.624 |
Total Extraordinary Items | 0 | -256.74 | -57.639 | -234.586 | |
Unusual Expense (Income) | -97.06 | 25.801 | 0 | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 6.89 | 2.381 | 0.063 | 0.071 | 1.519 |
Revenue | 6.89 | 2.381 | 0.063 | 0.071 | 1.519 |
Cost of Revenue, Total | 9.564 | 3.376 | 0.021 | 0 | 1.745 |
Gross Profit | -2.674 | -0.995 | 0.042 | 0.071 | -0.226 |
Total Operating Expense | 92.187 | -6.056 | -25.372 | 84.852 | 108.919 |
Selling/General/Admin. Expenses, Total | 40.349 | 37.354 | 30.707 | 33.402 | 36.694 |
Research & Development | 42.274 | 46.144 | 45.9 | 53.149 | 63.841 |
Operating Income | -85.297 | 8.437 | 25.435 | -84.781 | -107.4 |
Interest Income (Expense), Net Non-Operating | 2.679 | 2.825 | 0.369 | 0.383 | -0.426 |
Other, Net | 9.63 | 9.978 | 6.538 | 7.885 | 7.688 |
Net Income Before Taxes | -72.988 | 21.24 | 32.342 | -76.513 | -100.138 |
Net Income After Taxes | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
Net Income Before Extra. Items | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
Total Extraordinary Items | 0 | ||||
Net Income | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
Income Available to Common Excl. Extra. Items | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
Income Available to Common Incl. Extra. Items | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
Diluted Net Income | -72.908 | 21.24 | 32.232 | -76.52 | -100.138 |
Diluted Weighted Average Shares | 108.685 | 103.303 | 85.257 | 81.543 | 73.767 |
Diluted EPS Excluding Extraordinary Items | -0.67082 | 0.20561 | 0.37806 | -0.9384 | -1.35749 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.67082 | -0.69398 | -0.39959 | -0.95194 | -1.26749 |
Other Operating Expenses, Total | |||||
Unusual Expense (Income) | 0 | -92.93 | -102 | -1.699 | 6.639 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 199.488 | 336.52 | 1215.54 | 1152.17 | 1419 |
Cash and Short Term Investments | 180.327 | 299.503 | 1151.25 | 1106.46 | 1385.3 |
Cash & Equivalents | 113.006 | 161.16 | 317.705 | 327.214 | 402.579 |
Short Term Investments | 67.321 | 138.343 | 833.546 | 779.246 | 982.725 |
Prepaid Expenses | 8.374 | 25.628 | 37.472 | 32.888 | 19.762 |
Total Assets | 554.902 | 593.795 | 1781.25 | 1727.42 | 2242.84 |
Property/Plant/Equipment, Total - Net | 291.358 | 101.238 | 346.85 | 337.061 | 246.622 |
Property/Plant/Equipment, Total - Gross | 313.29 | 121.644 | 397.91 | 373.634 | 275.798 |
Accumulated Depreciation, Total | -21.932 | -20.406 | -51.06 | -36.573 | -29.176 |
Goodwill, Net | 5.646 | 5.646 | 13.128 | 13.128 | 13.128 |
Intangibles, Net | 4.868 | 0 | 10.041 | 14.326 | 13.169 |
Long Term Investments | 1.414 | 97.114 | 122.891 | 131.506 | 506.123 |
Other Long Term Assets, Total | 52.128 | 53.277 | 72.805 | 79.229 | 44.805 |
Total Current Liabilities | 128.237 | 152.993 | 203.588 | 223.58 | 146.431 |
Accounts Payable | 25.092 | 25.883 | 21.602 | 42.995 | 17.831 |
Accrued Expenses | 100.895 | 123.676 | 149.775 | 136.402 | 96.696 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.25 | 3.434 | 32.211 | 44.183 | 30.48 |
Total Liabilities | 358.559 | 219.518 | 426.196 | 442.431 | 357.774 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 153.319 |
Capital Lease Obligations | 0 | 153.319 | |||
Other Liabilities, Total | 230.322 | 66.525 | 222.608 | 218.851 | 58.024 |
Total Equity | 196.343 | 374.277 | 1355.06 | 1284.99 | 1885.07 |
Common Stock | 0.83 | 0.711 | 0.665 | 0.554 | 0.547 |
Additional Paid-In Capital | 4186.09 | 4096.4 | 4260.44 | 3568.18 | 3386.96 |
Retained Earnings (Accumulated Deficit) | -3986.5 | -3719.93 | -2900.55 | -2281.85 | -1498.81 |
Other Equity, Total | -4.07 | -2.911 | -5.505 | -1.893 | -3.627 |
Total Liabilities & Shareholders’ Equity | 554.902 | 593.795 | 1781.25 | 1727.42 | 2242.84 |
Total Common Shares Outstanding | 82.923 | 71.115 | 66.432 | 55.368 | 54.738 |
Total Receivables, Net | 0.4 | 0.4 | 0.019 | ||
Other Current Assets, Total | 10.787 | 11.389 | 26.414 | 12.426 | 13.912 |
Current Port. of LT Debt/Capital Leases | 0 | 1.424 | |||
Accounts Receivable - Trade, Net | 0.4 | 0.4 | |||
Total Inventory | 0 | ||||
Preferred Stock - Non Redeemable, Net | 0 | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 247.076 | 287.977 | 351.071 | 199.488 | 160.438 |
Cash and Short Term Investments | 174.293 | 245.303 | 318.257 | 180.327 | 139.633 |
Cash & Equivalents | 165.347 | 172.872 | 239.045 | 113.006 | 66.478 |
Short Term Investments | 8.946 | 72.431 | 79.212 | 67.321 | 73.155 |
Total Receivables, Net | 23 | ||||
Accounts Receivable - Trade, Net | 23 | ||||
Total Inventory | 20.969 | 13.642 | 3.809 | ||
Prepaid Expenses | 11.431 | 13.597 | 13.466 | 8.374 | 8.27 |
Other Current Assets, Total | 17.383 | 15.435 | 15.539 | 10.787 | 12.535 |
Total Assets | 613.608 | 663.393 | 692.736 | 554.902 | 520.098 |
Property/Plant/Equipment, Total - Net | 304.689 | 313.076 | 278.871 | 291.358 | 300.219 |
Property/Plant/Equipment, Total - Gross | 321.771 | 329.152 | 299.439 | 313.29 | 323.791 |
Accumulated Depreciation, Total | -17.082 | -16.076 | -20.568 | -21.932 | -23.572 |
Goodwill, Net | 5.646 | 5.646 | 5.646 | 5.646 | 5.646 |
Intangibles, Net | 5.368 | 5.49 | 5.613 | 4.868 | |
Long Term Investments | 0 | 0 | 0 | 1.414 | 1.407 |
Other Long Term Assets, Total | 50.829 | 51.204 | 51.535 | 52.128 | 52.388 |
Total Current Liabilities | 158.957 | 135.016 | 115.933 | 128.237 | 126.727 |
Accounts Payable | 19.852 | 10.894 | 19.235 | 25.092 | 18.622 |
Accrued Expenses | 121.455 | 118.272 | 91.54 | 100.895 | 105.004 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 17.65 | 5.85 | 5.158 | 2.25 | 3.101 |
Total Liabilities | 391.072 | 374.374 | 337.996 | 358.559 | 361.241 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 232.115 | 239.358 | 222.063 | 230.322 | 234.514 |
Total Equity | 222.536 | 289.019 | 354.74 | 196.343 | 158.857 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 1.071 | 1.065 | 1.064 | 0.83 | 0.829 |
Additional Paid-In Capital | 4333.59 | 4328.49 | 4322.02 | 4186.09 | 4181.39 |
Retained Earnings (Accumulated Deficit) | -4109.9 | -4038.17 | -3965.26 | -3986.5 | -4018.74 |
Other Equity, Total | -2.227 | -2.364 | -3.086 | -4.07 | -4.63 |
Total Liabilities & Shareholders’ Equity | 613.608 | 663.393 | 692.736 | 554.902 | 520.098 |
Total Common Shares Outstanding | 107.022 | 106.454 | 106.37 | 82.923 | 82.88 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -266.578 | -819.378 | -618.695 | -789.608 | -555.625 |
Cash From Operating Activities | -352.953 | -635.639 | -470.351 | -564.384 | -413.426 |
Cash From Operating Activities | 5.001 | 19.649 | 19.356 | 17.434 | 17.158 |
Non-Cash Items | -52.254 | 146.105 | 157.838 | 161.673 | 105.801 |
Cash Interest Paid | 0 | 0 | 0 | 15.494 | |
Changes in Working Capital | -39.122 | 17.985 | -28.85 | 46.117 | 19.24 |
Cash From Investing Activities | 250.453 | 562.557 | -84.345 | 507.807 | -679.435 |
Capital Expenditures | -13.208 | -23.003 | -28.986 | -76.252 | -55.737 |
Other Investing Cash Flow Items, Total | 263.661 | 585.56 | -55.359 | 584.059 | -623.698 |
Cash From Financing Activities | 54.253 | -93.954 | 546.715 | 21.187 | 737.692 |
Financing Cash Flow Items | 0 | -174.284 | 0 | 3.098 | |
Issuance (Retirement) of Stock, Net | 54.253 | 80.33 | 546.715 | 21.187 | 735.611 |
Net Change in Cash | -48.247 | -167.036 | -7.981 | -35.39 | -355.169 |
Issuance (Retirement) of Debt, Net | 0 | -1.017 | |||
Cash Taxes Paid | 0.253 | 0.617 | 0.361 | 0.637 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 21.24 | -266.578 | -298.81 | -222.29 | -122.152 |
Cash From Operating Activities | -86.638 | -352.953 | -296.68 | -219.654 | -125.296 |
Cash From Operating Activities | 1.082 | 5.001 | 3.745 | 2.358 | 1.014 |
Non-Cash Items | -87.074 | -52.254 | 44.053 | 32.613 | 22.606 |
Changes in Working Capital | -21.886 | -39.122 | -45.668 | -32.335 | -26.764 |
Cash From Investing Activities | 82.136 | 250.453 | 147.211 | 131.602 | 69.926 |
Capital Expenditures | -1.1 | -13.208 | -8.1 | -6.836 | -0.857 |
Other Investing Cash Flow Items, Total | 83.236 | 263.661 | 155.311 | 138.438 | 70.783 |
Cash From Financing Activities | 130.456 | 54.253 | 54.368 | 8.043 | 0.009 |
Issuance (Retirement) of Stock, Net | 130.456 | 54.253 | 54.368 | 8.043 | 0.009 |
Net Change in Cash | 125.954 | -48.247 | -95.101 | -80.009 | -55.361 |
Financing Cash Flow Items | 0 | ||||
Cash Taxes Paid | 0.002 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 15.2947 | 16358130 | -1407416 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.239 | 7742289 | 100261 | 2023-06-30 | LOW |
Tang Capital Management, LLC | Hedge Fund | 6.9029 | 7382827 | -2500000 | 2023-06-30 | MED |
PFM Health Sciences, LP | Hedge Fund | 6.8115 | 7285121 | 1263278 | 2023-06-30 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.1909 | 5551853 | 148970 | 2023-06-30 | LOW |
Granahan Investment Management, Inc. | Investment Advisor | 4.5406 | 4856322 | 3411065 | 2023-06-30 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 4.3634 | 4666813 | 1562062 | 2023-06-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 2.3372 | 2499715 | 0 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0755 | 2219758 | 121116 | 2023-06-30 | LOW |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 2.0103 | 2150054 | 739758 | 2023-06-30 | MED |
Columbia Wanger Asset Management, LLC | Investment Advisor | 1.8952 | 2026953 | 0 | 2023-08-31 | MED |
BofA Global Research (US) | Research Firm | 1.8088 | 1934599 | -30674 | 2023-06-30 | LOW |
Rafferty Asset Management LLC | Investment Advisor/Hedge Fund | 1.718 | 1837462 | 129019 | 2023-06-30 | MED |
Frazier Healthcare Partners | Venture Capital | 1.5988 | 1709907 | 269150 | 2023-06-30 | LOW |
Credit Suisse Funds AG | Investment Advisor/Hedge Fund | 1.5949 | 1705842 | 90091 | 2023-06-30 | LOW |
Pictet Asset Management (Japan) Ltd. | Investment Advisor | 1.4491 | 1549818 | 763570 | 2023-04-30 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.2948 | 1384820 | -1211649 | 2023-06-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.914 | 977570 | 518614 | 2023-06-30 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 0.8923 | 954388 | -469533 | 2023-06-30 | MED |
Jane Street Capital, L.L.C. | Research Firm | 0.8913 | 953295 | 439219 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Bluebird Company profile
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.Industry: | Bio Therapeutic Drugs |
455 Grand Union Boulevard
SOMERVILLE
MASSACHUSETTS 02145
US
Income Statement
- Annual
- Quarterly
News
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?
UK banks will be in the spotlight in the week ahead as the European earnings season continues
16:38, 16 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com